Nyxoah (NASDAQ:NYXH) reported 13% sequential worldwide net revenue growth in the first quarter of 2026, driven primarily by continued adoption of its Genio system in the United States, where the company is in its second full quarter of commercialization.
Chief Executive Officer Olivier Taelman said
Nyxoah SA (NASDAQ: NYXH; Euronext Brussels: NYXH) is a Belgium-based medical technology company making significant strides in the treatment of Obstructive Sleep Apnea (OSA). The company is currently in focus due to its innovative Genio® system, a patient-centric, minimally invasive, and leadless hypoglossal neurostimulation therapy designed for moderate to severe OSA. As of December 17, [...]
Nyxoah expects the stronger reimbursement framework to support broader adoption, increase procedural throughput, and expand across Medicare-heavy institutions.
Minneapolis, MN – October 13, 2025 – Inspire Medical Systems (NYSE: INSP) emerged as a standout performer in today's trading session, witnessing its stock price jump by an impressive 3.9% by the closing bell. This significant surge is primarily attributed to the overwhelmingly positive clinical outcomes data presented for its next-generation
Nyxoah CEO Olivier Taelman said that the company has also trained surgeons, obtained Value Analysis Committee approvals, and achieved successful coverage from major payors.
